BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 15717252)

  • 1. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
    Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
    Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005].
    Wellhöfer B
    Dtsch Med Wochenschr; 2006 Feb; 131(6):284. PubMed ID: 16463237
    [No Abstract]   [Full Text] [Related]  

  • 5. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for Alzheimer disease.
    Can Fam Physician; 2005 Nov; 51(11):1485. PubMed ID: 16353830
    [No Abstract]   [Full Text] [Related]  

  • 8. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
    Crutchfield D
    Director; 2008; 16(1):19-21. PubMed ID: 19343870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
    Virta L; Viramo P
    J Am Geriatr Soc; 2007 Nov; 55(11):1886-7. PubMed ID: 17979907
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
    Aisen PS
    J Am Acad Nurse Pract; 2005 Mar; Suppl():5-7. PubMed ID: 16033023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: Seeing the signs early.
    Leifer BP
    J Am Acad Nurse Pract; 2009 Nov; 21(11):588-95. PubMed ID: 19900220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Memantine: the value of combined therapy].
    Molinuevo JL
    Rev Neurol; 2011 Jan; 52(2):95-100. PubMed ID: 21271549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for Alzheimer's disease.
    Cranwell-Bruce LA
    Medsurg Nurs; 2010; 19(1):51-3. PubMed ID: 20336985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.